Treatment of Huntington's chorea with bromocriptine.
The authors tested the effects of 2-Br-ergocriptine (bromocriptine, CB-154), a drug which exerts a mixed agonist-antagonist activity on the dopaminergic receptors, in 12 patients with Huntington Chorea in a double-blind crossover trial. This treatment significantly reduced the abnormal involuntary movements and the disease severity in most of the patients. Subjects who were slightly disabled showed a better response than the ones with more severe degrees of disability.
D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005684:Gait; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013037:Spatial Behavior; D013060:Speech
D004873:Ergolines; D010919:Placebos; D001971:Bromocriptine